
10X Genomics (TXG) Stock Forecast & Price Target
10X Genomics (TXG) Analyst Ratings
Bulls say
10x Genomics has demonstrated a robust market presence, evidenced by the meaningful increase in Chromium reaction volumes, suggesting continued demand amidst challenges in the pharmaceutical sector. The company's consumables are projected to grow significantly, with estimates indicating a 5-19x increase by 2027, outpacing instrument revenue growth. This momentum in consumables aligns well with the company's integrated solutions for analyzing biological systems, providing a strong foundation for future financial performance.
Bears say
10x Genomics experienced a contraction in 2024, marked by double-digit pricing pressure that negatively impacted revenues, alongside flat to modestly lower volumes, with growth not anticipated to resume until 2027. The company reported weaker than expected fourth-quarter results, including an earnings per share miss and a full-year revenue outlook that fell short of market expectations. Since reaching peak stock prices in 2021, 10x Genomics has seen its stock decline by over 90%, as its market segments have not expanded to the levels anticipated by analysts.
This aggregate rating is based on analysts' research of 10X Genomics and is not a guaranteed prediction by Public.com or investment advice.
10X Genomics (TXG) Analyst Forecast & Price Prediction
Start investing in 10X Genomics (TXG)
Order type
Buy in
Order amount
Est. shares
0 shares